Table 2.
Summary of the data from the recent studies on the use of megaprosthesis for the management of massive skeletal defects in distal humerus and elbow.
| Authors | Diagnosis | No of patients | Average age (years) | Average Follow up | Clinical outcome | Radiological Outcome | Complications | Result | Survival |
|---|---|---|---|---|---|---|---|---|---|
| Goulding et a.12 | Tumors and Failed TER | 13 (CPS) | 45 | 68 m | – | – | 2 lack of CPS fixation (one breakage) | 6 revisions | – |
| 2 loosening of ulnar component | |||||||||
| 3 PH | 1 bushing wear | ||||||||
| 6 DH | 1 infection | ||||||||
| 1 SOH | 2 GH subluxation | ||||||||
| Capanna et al.13 | 31 Tumors | 36 | 60.1 | 25 m | MEPS = 77.08 | 3 RNP | 23 deaths from disease | 93% at 5 years | |
| 5 Failed | MSTS = 22.9 | 1 UNP | 5-year survival = 25.1% | ||||||
| TER | 1 infection | ||||||||
| 1 disassembly | |||||||||
| Abdullah et a.14 | 2 Failed TER | 3 | – | 6–24 m | DASH = 53.76 | – | None had any complications | – | – |
| 1 Failed TER + SHA | |||||||||
| Tang et al.15 | Tumors | 25 | 38.1 | 45.4 m | MSTS = 23.9 | 2 aseptic loosening of the ulnar component | 4 revisions | 11 deaths from disease | – |
| 2 aseptic loosening of the humeral component | 4 recurrence | ||||||||
| 2 nerve palsy and transient vascular compromise | |||||||||
| Weber et al.16 | Tumor and Failed TER/APC | 23 | 46 | 46 m | MSTS = 23 | 5 stable Allograft | 1 ulnar nerve transection | 8 deaths from disease | – |
| 7 THRE | 3 stable periprosthetic lysis around ulnar component | 1 UNP | 3 deaths unrelated to disease | ||||||
| 5 APC 11 TER | 2 loosening of humeral component | 1 RNP | |||||||
| 1 PINP | |||||||||
| 2 infections |
Abbreviations: m = months, TER = Total Elbow Replacement, MEPS = Mayo Elbow Performance Score, MSTS = Musculoskeletal Tumor Society Score, DASH = Disabilities of Arm Shoulder and Hand Score, RNP = Radial Nerve Palsy, UNP = Ulnar Nerve Palsy, THRE = Total Humeral Replacement Endoprostheis, APC = Allograft Prosthesis Composite, PIN = Posterior Interosseous Nerve, SHA = Shoulder Hemireplacement Arthroplasty.